Novel naphthyridines are histamine H3 antagonists and serotonin reuptake transporter inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 9, 2007, Pages 2566-2569

  Letavic, Michael A ^a   Keith, John M ^a   Ly, Kiev S ^a   Barbier, Ann J ^a   Boggs, Jamin D ^a   Wilson, Sandy J ^a   Lord, Brian ^a   Lovenberg, Timothy W ^a   Carruthers, Nicholas I ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Histamine H3 antagonists; Naphthyridines; Serotonin reuptake inhibitors

Indexed keywords

1,2,3,4 TETRAHYDRO 2,6 NAPHTHYRIDINE DERIVATIVE; HISTAMINE H3 RECEPTOR ANTAGONIST; LIGAND; NAPHTHYRIDINE DERIVATIVE; NITROSTYRENE; SEROTONIN UPTAKE INHIBITOR; STYRENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CYCLIZATION; DRUG SYNTHESIS; HUMAN; NONHUMAN; RAT; REACTION ANALYSIS; REDUCTION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HISTAMINE; HISTAMINE ANTAGONISTS; HUMANS; MODELS, CHEMICAL; MOLECULAR CONFORMATION; NAPHTHYRIDINES; RATS; RECEPTORS, HISTAMINE H3; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 33947731437     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.02.006     Document Type: Article

References (25)

1. Jane-Llopis E., Hosman C., Jenkins R., and Anderson P. Br. J. Psychiatry; J. Mental Sci. 183 (2003) 384
2. Quraishi S., and Frangou S. J. Affect. Dis. 72 (2002) 209
3. Tylee A., Gastpar M., Lepine J.P., and Mendlewicz J. Int. Clin. Psychopharmacol. 14 (1999) 139
4. Nierenberg A.A., Keefe B.R., Leslie V.C., Alpert J.E., Pava J.A., Worthington III J.J., Rosenbaum J.F., and Fava M. J. Clin. Psychiatry 60 (1999) 221
5. Fava G.A., Fabbri S., and Sonino N. Prog. Neuro-Psychopharmacol. Biol. Psych. 26 (2002) 1019
6. Beasley Jr. C.M., Koke S.C., Nilsson M.E., and Gonzales J.S. Clin. Ther. 22 (2000) 1319
7. Zajecka J.M. J. Clin. Psychiatry 61 Suppl. 2 (2000) 20
8. Saper C.B., and Scammell T.E. Sleep 27 (2004) 11
9. Turner D.C., Clark L., Dowson J., Robbins T.W., and Sahakian B.J. Biol. Psychiatry 55 (2004) 1031
10. Turner D.C., Clark L., Pomarol-Clotet E., McKenna P., Robbins T.W., and Sahakian B.J. Neuropsychopharmacology 29 (2004) 1363
11. Jasinski D.R., and Kovacevic-Ristanovic R. Clin. Neuropharmacol. 23 (2000) 149
12. Robertson Jr. P., and Hellriegel E.T. Clin. Pharmacokinet. 42 (2003) 123
13. Witkin J.M., and Nelson D.L. Pharmacol. Ther. 103 (2004) 1
14. Monti J.M., Jantos H., Boussard M., Altier H., Orellana C., and Olivera S. Eur. J. Pharmacol. 205 (1991) 283
15. Monti J.M., Jantos H., Ponzoni A., and Monti D. Neuropsychopharmacology 15 (1996) 31
16. Barbier A.J., Berridge C., Dugovic C., Laposky A.D., Wilson S.J., Boggs J., Aluisio L., Lord B., Mazur C., Pudiak C.M., Langlois X., Xiao W., Apodaca R., Carruthers N.I., and Lovenberg T.W. Br. J. Pharmacol. 143 (2004) 649
17. Apodaca R., Dvorak C.A., Xiao W., Barbier A.J., Boggs J.D., Wilson S.J., Lovenberg T.W., and Carruthers N.I. J. Med. Chem. 46 (2003) 3938
18. Maryanoff B.E., Vaught J.L., Shank R.P., McComsey D.F., Costanzo M.J., and Nortey S.O. J. Med. Chem. 33 (1990) 2793
19. Keith J.M., Gomez L.A., Letavic M.A., Ly K.S., Jablonowski J.A., Seierstad M., Barbier A.J., Wilson S.J., Boggs J.D., Fraser I.C., Mazur C., Lovenberg T.W., and Carruthers N.I. Bioorg. Med. Chem. Lett. 17 (2007) 702-706
20. Letavic M.A., Keith J.M., Jablonowski J.A., Stocking E.M., Gomez L.A., Ly K.S., Miller J.M., Barbier A.J., Bonaventure P., Boggs J.D., Wilson S.J., Miller K.L., Lord B., McAllister H.M., Tognarelli D.J., Wu J., Abad M.C., Schubert C., Lovenberg T.W., and Carruthers N.I. Bioorg. Med. Chem. Lett. 17 (2007) 1047
21. Dvorak C.A., Apodaca R., Barbier A.J., Berridge C.W., Wilson S.J., Boggs J.D., Xiao W., Lovenberg T.W., and Carruthers N.I. J. Med. Chem. 48 (2005) 2229
22. Leeson P.D., and Emmett J.C. J. Chem. Soc., Perkin Trans. 1 (1988) 3085
23. Gu Y.G., Bayburt E.K., Michaelides M.R., Lin C.W., and Shiosaki K. Bioorg. Med. Chem. Lett. 9 (1999) 1341
24. 3 receptor and the rat SERT.
25. i = 4 nM (see Carruthers, N. I.; Gomez, L. A.; Jablonowski, J. A.; Keith, J. M.; Letavic, M. A.; Ly, K. S.; Miller, J. M. B.; Stocking, E. M.; Wolin, R. L. PCT Int. Appl. 2006, WO 2006066197 A1), also indicating that there is a preference against the presence of the nitrogen atom in the 2,5-naphthyridine structure, particularly with respect to SERT affinity.